Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development.

Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA pre-targeted radioimmunotherapy for relapsed non-Hodgkin lymphoma.

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma ...

Nuclear medicine can help diagnose and treat different health conditions, including some forms of cancer. Learn what it's all about.

The targeted delivery of radionucleotides into tumors, known as radioimmunotherapy (RIT), has proven effective mainly in hematological cancer treatment, but its usefulness in solid tumors needs ...

The agents, sequence, dose, fractionation, and irradiated sites required further exploration. What are some of the unique follow-up needs for long-term NSCLC survivors after radioimmunotherapy?

Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT) – An ASCO Reading Room selection March 8, 2024 • 2 min read ...

A new trial from Italy challenges a decades-old assumption that autologous stem cell transplant is more effective than radioimmunotherapy for consolidation after follicular lymphoma relapse.

Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT) The following represents disclosure information provided by authors of this manuscript. All ...